Comment on

• TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49.

  Brenner PC, Rettig WJ, Sanz-Moncasi MP, Reuter V, Aprikian A, Old LJ, Fair WR, Garin-Chesa P. Brenner PC, et al. J Urol. 1995 May;153(5):1575-9. J Urol. 1995. PMID: 7536270
• The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer.

  Daliani DD, Eisenberg PD, Weems J, Lord R, Fueger R, Logothetis CJ. Daliani DD, et al. J Urol. 1995 May;153(5):1587-91. J Urol. 1995. PMID: 7536271 Clinical Trial.
• Lewis Y antigen as detected by the monoclonal antibody BR96 is expressed strongly in prostatic adenocarcinoma.

  Myers RB, Srivastava S, Grizzle WE. Myers RB, et al. J Urol. 1995 May;153(5):1572-4. J Urol. 1995. PMID: 7714977
• Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.

  Lundgren R, Nordle O, Josefsson K. Lundgren R, et al. J Urol. 1995 May;153(5):1580-6. J Urol. 1995. PMID: 7714978 Clinical Trial.